Back to search

Democritus University of Thrace (DUTH)

Μέθοδοι συστημικής βιοπληροφορικής για την μελέτη των αλληλεπιδράσεων μικροβιώματος και βλεννογονίου ανοσολογικής απόκρισης ως στόχος νέων θεραπευτικών στρατηγικών

Abstract

dc:description

Background. Mucosal immunology is a crucial part of the body’s defense against pathogens and the external environment. The mucosa operates selectively against harmful microorganisms and allows for the host’s symbiosis with commensal microbiota. The gastrointestinal tract contains the biggest mucosal surface in the human body and provides the perfect breeding ground for the microbiota due to its large and complex architecture. During homeostasis, the microbiota’s role is diverse and includes signaling and defense versus pathogens and inflammation (by interacting with the mucosa), vitamin production, digestive aid and metabolism of important nutrients. The genetic composition of all the microbes in a host is called the microbiome and has been implicated as a contributing factor and a deterrent in a variety of pathological conditions varying from neurological to cardiovascular and gastrointestinal. The compositional diversity of the gut microbiome is unique for each person and is influenced by geographic, lifestyle and environmental conditions. Perhaps the strongest associations between disease and microbial dysbiosis (the pathological imbalance of microbial communities) have been studied and observed in Inflammatory Bowel Diseases (IBD). IBD and their two main manifestations, Crohn’s Disease (CD) and Ulcerative Colitis (UC), are ideal for the study of the interactions between mucosal immunology and the microbiome due to their inflammatory background, their occurrence in the GI tract and their yet unknown etiology which involves both innate and adaptive immunity. CD, in particular, adds another complex pathophysiological layer with its fibrotic complications. Because of their complex background, the study of IBD requires multifaceted approaches for the elucidation of their molecular profile. Multi-omics approaches, which include genomics, epigenomics, transcriptomics, metabolomics proteomics and the study of the microbiome provide a unique perspective and in depth-knowledge on the pathophysiology and etiopathology of IBD (IBD-omics). Each of these methodologies relies on the production and analysis of a vast amount of biological information, far exceeding the human processing capabilities. Hence, the need for computational assistance arises and with it the scientific field of bioinformatics and especially systems bioinformatics which focuses on the interactions of these approaches. Aim and objectives. Aim of this thesis is to use system bioinformatics methods to search for and analyze interactions between the mucosal immune response and the gut microbiome using the involvement of the intestinal microflora in homeostatic and inflammatory activity as our main model. The focus is on exploring new molecular targets for therapeutic strategies in the treatment of IBD by searching through genetic, protein and metabolic features of the host and the gut microbiome alike. Materials and Methods. Depending on the molecular function under study a multitude of methodologies has been applied on patient samples and publicly available data. Phenotypes and sub-phenotypes of CD and UC were targeted in order to better classify these diseases and characterize individual molecular profiles. To study the genetic and proteomic background of IBD, SNPs associated with both CD and UC, and their sub-phenotypes (as those are characterized in the Montreal classification system), were obtained via a customized IBD risk GWAS panel performed on Greek patient samples. These SNPs were statistically associated with each phenotype via PLINK and then used as input for 2 distinct pipelines for pathway analysis via the KEGG database to detect functional interactions. The first one involved the bioinformatics tool PathwayConnector for the creation of complementary networks of interacting pathways, and the second via the STRING platform provided protein-protein association networks and the pathways those involve. Network analysis metrics, specifically network centralities, were utilized to identify proteins exhibiting significant IBD involvement and to subsequently rank the signaling pathways those proteins participate in. In addition, this has allowed for the construction of a network of pathological conditions which share parts of their molecular background with IBD. To study mucosa-microbial interactions a metagenomic in silico pipeline was implemented to study microbial diversity, taxonomic abundance, microbe-disease associations and microbial metabolism between the behavioral sub-phenotypes of CD (B1 non‐stricturing non‐penetrating, B2 stricturing and B3 penetrating). 16s rRNA sequencing data were obtained from two, publicly available via the QIITA microbial study management platform, CD patient versus healthy control datasets consisting of two, geographically distinct, populations. The bioinformatics tools and algorithms QIIME, Calypso, LEfSe, PICRUSt and STAMP were employed for the analyses. To study gene function during CD and the mechanisms behind fibrosis, expression data were obtained from publicly available microarray datasets via Gene Expression Omnibus. These datasets contained data from Crohn’s Disease, Idiopathic Pulmonary Fibrosis (IPF), Systematic Scleroderma (SSc), Chronic Kidney Disease (CKD) and Liver Cirrhosis (LC) patients versus healthy controls. Each dataset was studied independently, to avoid bias due to different experimental conditions, using bioinformatics differential gene expression analysis via the GEO2R tool. Two separate groups were created containing combinations of dataset intersections calculated by the SuperExactTest R package. These groups contained the statistically significant (p < 0.05) differentially expressed genes versus healthy controls from the datasets of CD and the other fibrotic disorders. The intersection of these two groupings provided a gene signature for pathway analysis via the Reactome database. In addition, network analytics were applied to two tissue-specific, gene co-expression networks constructed by all the genes expressed on human terminal ileum and sigmoid to identify the molecular etiology behind topological preference of fibrosis during CD.Finally, to identify drugs and chemical compounds which can be used in IBD treatment regimens a computational drug repositioning pipeline was applied to the CD differential gene expression data obtained previously. The statistically significant genes (p < 0.05) of each dataset were split into two categories containing genes upregulated or downregulated versus healthy controls. The intersection of all CD datasets created a de novo CD gene signature. This signature was used as input for a) REACTOME to identify etiopathogenetic mechanisms of CD and b) CLUE.IO to identify compounds which reverse or amplify it. ResultsIn total 41 different loci were associated with IBD phenotypes versus Healthy Controls through our PLINK analysis. Four were found to be shared by CD and UC, three between B1 and B2 CD sub-phenotypes and none between the E1 and E3 UC sub-phenotypes. The complementary pathways and enriched protein-protein association networks revealed novel and well established molecular components of IBD, such as pathways involving apoptosis, Jak-STAT, PI3K-Akt, TNF, T-cell and B-cell receptor, MAPK and TLR signaling pathways. Also, 44 diseases were found to share molecular mechanisms with the IBD phenotypes and sub-phenotypes. The analyses established that IBD sub-phenotypes have distinct genetic and molecular profiles that can contribute to their accurate identification and classification. The analysis of the gut microbiome in association with the behavioral CD sub-phenotypes showed decreased biodiversity within all 3 Crohn’s disease sub-phenotypes versus healthy controls with the most pronounced reductions in B2 and B3 compared to B1. The complex B2 and B3 sub-phenotypes exhibited similar enterotypes to each other and different from those of B1 and healthy controls. The same pattern was highlighted by the differential abundance, correlation coefficient and microbial metabolic analyses where B1 was behaving differently than B2 and B3. Finally, several microbial taxa were highlighted as potential biomarkers for the classification of all sub-phenotypes and disease progression. These findings establish that there are distinct differences in complicated Crohn’s disease sub-phenotypes versus B1 and healthy controls. The study into the molecular background of fibrosis revealed 7 common DE genes among all CD datasets (CXCL1, ICAM1, PHLPP2, ZKSCAN1, ATP9A, NCF4, CACNA2D1). The intersection of all fibrotic disease differentially expressed genes versus healthy controls, showed 241 common genes contributing to 12 pathways associated with fibrosis and 17 with inflammation/immune response. Tissue-specific co-expression networks revealed 122/241 genes expressed on the terminal ileum and only 32/241 on the sigmoid. Regarding signaling pathways, 9 fibrosis- and 6 inflammation-related ones were featured on terminal ileum and only 1 fibrosis- and 5 inflammation-related on the sigmoid. Finally, trying to find drugs and chemical compounds which are beneficial or harmful for CD several thousand differentially expressed genes versus healthy controls were identified. Their intersection highlighted 39 upregulated and 12 downregulated genes for a de novo gene signature. These, respectively, were implicated in 26 and 52 inflammatory and immunological signaling pathways. In total, 22 compounds were found to reverse the gene signature and could be examined for drug repositioning, whereas. 33 amplify it and might be involved in CD exacerbation. Interestingly, no significant correlation was found between the common clinical practice drugs and the IBD gene signature, indicating no interactions. Conclusions. This work establishes distinct differential molecular and microbial backgrounds of IBD phenotypes and sub-phenotypes through the utilization of systems bioinformatics approaches and traditional bioinformatics tools. It showcases how their genetic variation, gene expression, metabolomic and microbiome differences can be interpreted and associated with innate and acquired immunity mechanisms via the mucosa allowing for specific classification and unique identification of molecular and microbial therapeutic targets. Finally, this thesis sets the ground for combinational approaches in future works.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Dovrolis, Nikolas
  • Δόβρολης, Νικόλαος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/46467

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Dovrolis, Nikolas; Δόβρολης, Νικόλαος. Μέθοδοι συστημικής βιοπληροφορικής για την μελέτη των αλληλεπιδράσεων μικροβιώματος και βλεννογονίου ανοσολογικής απόκρισης ως στόχος νέων θεραπευτικών στρατηγικών. Democritus University of Thrace (DUTH), 2019. http://hdl.handle.net/10442/hedi/46467